Table 3 Patient and tumor related characteristics affecting distant metastasis and progression-free survival outcomes.

From: Management of Low and Intermediate Risk Adult Rhabdomyosarcoma: A Pooled Survival Analysis of 553 Patients

Characteristics

Distant Metastasis Free Survival (DMFS)

Progression Free survival (PFS)

Univariate

Multivariate analysis

Univariate

Multivariate analysis

p-value

Patients

Events

HR

95% CI

Test C-index

p-value

Patients

Events

HR

95% CI

Test C-index

Age (yr)

 < 0.001 a

390

94

1.13

0.92–1.373

61%

 < 0.001

342

113

1.32

1.082–1.61

70%

Tumor size (cm)

0.008

204

52

1.06

0.845–1.327

62%

0.008

178

58

1.03

0.85–1.25

69%

Gender (Male)

0.091

380

93

1.50

0.98–2.286

67%

0.987

333

112

1.14

0.782–1.66

71%

Tumor Site

Head/Neck (Non PM)

 < 0.001

390

94

0.18

0.055–0.565

61%

0.001

342

113

0.32

0.153–0.681

70%

Orbit

0.817

390

94

0.96

0.30–3.044

61%

0.452

342

113

0.70

0.22–2.218

70%

GU (Non B/P)

0.126

390

94

1.16

0.70–1.894

61%

0.005

342

113

1.08

0.645–1.798

69%

GU (B/P)

0.002

390

94

2.11

0.89–4.94

61%

 < 0.001

342

113

1.91

0.889–4.11

70%

Extremities

0.079

390

94

0.82

0.39–1.727

62%

0.207

342

113

1.22

0.55–2.65

70%

Head/Neck (PM)

      

0.055

342

113

0.87

0.53–1.428

69%

Histopathological subtype

Botryoides/Spindle cell

0.046

389

93

1.14

0.54–2.39

60%

0.234

341

112

1.65

0.90–2.99

68%

Embryonal

0.003

389

93

1.02

0.628–1.66

60%

0.001

341

112

0.78

0.499–1.2117

69%

Alveolar

0.044

389

93

0.91

0.53–1.539

59%

0.032

341

112

1.03

0.621–1.713

69%

Pleomorphic

0.080

389

93

0.80

0.46–1.383

60%

0.161

341

112

0.79

0.429–1.44

70%

IRS stage

Stage I

 < 0.001

347

75

1.17

0.694–1.98

62%

 < 0.001

302

91

0.92

0.55–1.538

68%

Stage II

0.741

347

75

0.64

0.29–1.413

63%

0.058

302

91

1.39

0.760–2.558

68%

UICC stage

UICC stage I

 < 0.001

265

59

0.39

0.206–0.722

69%

 < 0.001

240

77

0.87

0.466–1.604

70%

UICC stage II

0.027

265

59

1.22

0.701–2.137

60%

0.013

240

77

1.03

0.624–1.685

70%

Tumor status

 < 0.001

268

66

1.93

1.127–3.313

67%

 < 0.001

239

80

1.38

0.80–2.35

70%

Nodal status

0.001

324

69

2.01

1.184–3.398

62%

0.070

287

90

1.01

0.60–1.689

70%

IRS Risk group

 < 0.001

390

94

3.37

2.05–5.536

61%

 < 0.001

342

113

1.96

1.237–3.115

70%

  1. aBold = significant values (p < 0.05); PM: para-meningeal; GU: Genitourinary; B/P: Bladder/Prostate; IRS: Intergroup Rhabdomyosarcoma Study; UICC: International Union Against Cancer TNM staging guidelines; For the multivariate models, each variable was adjusted to the following set of covariates: DMFS analysis: Age, Head/Neck (Non PM) tumor site, GU (B/P) tumor site, and IRS risk group; PFS analysis: Age, Head/Neck (Non PM) tumor site, IRS Post-Surgical Group-I, IRS Post-Surgical Group-II and IRS risk group. Empty rows correspond to covariates that were not entered into the model because they were either explained by other covariates or did not meet the model inclusion criteria (due to small number of events or other reasons - see Methodology section for details).
Back to article page